Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125320 · ClinicalTrials.gov registry record · Phase 3
Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
NCT00125320 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 190 participants.
The verdict
NCT00125320, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and efficacy of RSD1235 compared to placebo in the conversion of atrial arrhythmia to sinus rhythm in subjects following valvular and/or coronary artery bypass graft surgery.
Interventions
- DRUG RSD1235
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125320
The ClinicalTrials.gov registry entry for NCT00125320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RSD1235 is the first listed.
NCT00125320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125320 about?
NCT00125320 is a clinical study titled "Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery". The purpose of this study is to demonstrate the safety and efficacy of RSD1235 compared to placebo in the conversion of atrial arrhythmia to sinus rhythm in subjects following valvular and/or coronary artery bypass graft surgery.
What is the current status of trial NCT00125320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2004-06. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00125320?
The interventions under investigation include: RSD1235 (DRUG).
Who is sponsoring clinical trial NCT00125320?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.